Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome - 30/11/11
Doi : 10.1016/j.jaci.2011.05.023
Heleen D. de Koning, MD a, b, c, d 
, Joost Schalkwijk, PhD b, c, d, Jos W.M. van der Meer, MD, PhD a, c, Anna Simon, MD, PhD a, c
, Joost Schalkwijk, PhD b, c, d, Jos W.M. van der Meer, MD, PhD a, c, Anna Simon, MD, PhD a, c a Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
b Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
c Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
d Nijmegen Centre for Molecular Life Sciences (NCMLS), Nijmegen, The Netherlands
| Novartis supplied canakinumab for free and provided some financial support. H.D.d.K. is supported by a grant of the Nijmegen Institute for Infection, Inflammation and Immunology (N4i) and grant no. 92003527 of the Netherlands Organisation for Health Research and Development (ZonMw). A.S. is supported by a VIDI grant of ZonMW. |
|
| Disclosure of potential conflict of interest: H. D. de Koning has received research support from Novartis. J. W. M. van der Meer has received consulting fees from Novartis. A Simon has received consulting fees and research support from Novartis. J. Schalkwijk has declared that he has no conflicts of interest. |
© 2011
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 128 - N° 6
P. 1352-1354 - décembre 2011 Retour au numéro
Article précédent
- Low prevalence of IgE to cross-reactive carbohydrate determinants in beekeepers
- Francisco-Javier Carballada, Arturo Gonzalez-Quintela, Ramón Nuñez, Carmen Vidal, Manuel Boquete
- Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies
- Soumya D. Chakravarty, Arthur F. Yee, Stephen A. Paget
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?